home / stock / cdxs / cdxs news

CDXS News and Press, Codexis Inc. From 10/21/21

Stock Information
Company Name: Codexis Inc.
Stock Symbol: CDXS
Market: NASDAQ
Website: codexis.com
Menu
CDXS CDXS Quote CDXS Short CDXS News CDXS Articles CDXS Message Board
Get CDXS Alerts

News, Short Squeeze, Breakout and More Instantly...
CDXS - Codexis to Report Third Quarter 2021 Financial Results on November 4

REDWOOD CITY, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that it will report its financial results for the third quarter of 2021 on Thursday, November 4, 2021, followi...
CDXS - Up Over 500% in the Last 5 Years, Can This Biotech Continue Its Hot Streak?

Less waste, increased yield, better performance. This is the mantra of biologic manufacturer Codexis (NASDAQ: CDXS) , which produces optimized enzymes to enhance the yield of current chemistry methods by traditional pharmaceutical companies. By providing a more sustainable and effic...

CDXS - Codexis, Almelo and RC2 Announce a Tri-Party Collaboration for the Enzymatic Production of Low Cost Sitagliptin API for the Generic Market, Including a License to Codexis Enzyme Technology in India

REDWOOD CITY, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced a tri-party collaboration agreement with Almelo Private, Ltd., an Indian producer of active pharmaceutical ingredie...

CDXS - Progenity, Biomerica leads healthcare gainers; Omeros, Adagio Therapeutics among major losers

Gainers: Progenity (NASDAQ:PROG) +29%, Biomerica (NASDAQ:BMRA) +28%, Atea Pharmaceuticals (NASDAQ:AVIR) +19%, Silverback Therapeutics (NASDAQ:SBTX) +13%, Codexis (NASDAQ:CDXS) +12%. Losers: Omeros (NASDAQ:OMER) -41%, Adagio Therapeut...
CDXS - Codexis and Merck Amend and Extend Supply Agreement for Enzyme Used in Manufacture of Sitagliptin

REDWOOD CITY, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced the amendment and extension of its agreement with Merck, known as MSD outside the United States and Canada, to lic...

CDXS - Codexis Confirms Receipt of Follow-on Orders for Proprietary Enzyme Product from Undisclosed Global Pharmaceutical Company

REDWOOD CITY, Calif., Aug. 25, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced the Company received new purchase orders with an aggregate total value of approximately $15 million for the 2021 su...

CDXS - Codexis, Inc. 2021 Q2 - Results - Earnings Call Presentation

The following slide deck was published by Codexis, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Codexis, Inc. 2021 Q2 - Results - Earnings Call Presentation

CDXS - Codexis EPS beats by $0.10, beats on revenue

Codexis (NASDAQ:CDXS): Q2 GAAP EPS of -$0.07 beats by $0.10. Revenue of $25.45M (+70.0% Y/Y) beats by $7.13M. Press Release For further details see: Codexis EPS beats by $0.10, beats on revenue

CDXS - Codexis Reports Second Quarter 2021 Financial Results

Record Product Revenue of $14.7M, up 227% YOY Record Product Gross Margin of 71% Company Raises Guidance for 2021 Total Revenue to $98 - 103 M and 2021 Product Revenue to $59 - 63 M REDWOOD CITY, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), ...

CDXS - Codexis and Kalsec Announce Expanded Collaboration for Supply of Novel Enzyme to Sustainably Produce Natural Clean-Label Beverage Ingredient

REDWOOD CITY, Calif. and KALAMAZOO, Mich., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, and Kalsec, Inc., a leading global producer of natural spice and herb extracts, colors, food protection ...
Previous 10 Next 10